This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Velafermin

Celldex Therapeutics, Inc.

Drug Names(s): CG53135, Fibroblast Growth Factor-20, FGF-20

Description: CG53135 is a novel investigational protein therapeutic (FGF-20) that promotes both epithelial and mesenchymal cell proliferation in vitro and demonstrated activity in multiple animal models.

Deal Structure: CG53135 was originally developed by CuraGen.

In May 2009, Celldex Therapeutics announced it entered into a definitive agreement to acquire CuraGen. In October 2009, Celldex Therapeutics announced the successful completion of its acquisition of CuraGen Corporation.


Velafermin News

Pink Sheet CuraGen velafermin


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug